

Draft Agenda

1st Core Group Meeting

Lisbon 9 January 2019 from 9:30 to 17:00

1. Welcome to participants

2. Adoption of agenda

3. Reporting of coordination activities:

- Grant Agreement
- Financial Reporting
- Scientific/networking Reporting and Monitoring

----- Coffee break -----

4. Presentation and discussion of the advances in the Action

- Objectives, deliverables, tasks and timeline
- Working Groups
- Other management roles/structures
 - STSMs rules, planning, application form, assessment, model final report
 - Training schools rules, planning, assessment, satisfaction
- Implementation of COST policies on the promotion of Inclusiveness and Excellence, gender balance and Early Career Investigators (ECI)

----- Lunch break -----

5. Action implementation planning

- Monitoring of the Objective Achievement Indicators for MoU Objectives
- Activity and budget planning (Work and Budget Plan preparation)
- Dissemination strategy/ planning (Publications and outreach activities)
 - Webpage, social media, initiatives to spread information on the activities and increase visibility to broaden the network
- Monitoring & Assessment of the progress and allocation of funds of the Action

6. Any Other Business (AOB)

7. Closing

TASKS AND DELIVERABLES 1ST GRANT PERIOD 1 NOV 2018 TO 30 APRIL 2019

TASKS	DELIVERABLES
WG 1 IN DEPTH PHENOTYPING DILI	
<ul style="list-style-type: none"> ✓ Harmonize nomenclature, clinical measurements, definitions, classification and outcomes ✓ Standardize forms for prospective multicentre data collection, established and possibly novel and improved causality assessment tools; 	<ul style="list-style-type: none"> ✓ Standardized approach to diagnosis and SOPs for data/samples collection ✓ Coordination of the development of pre-funded database of DILI patients providing a framework for the access to patient cohorts from different EU countries ✓ A workshop on DILI diagnosis, classification and management for developing improved skills in scientific and clinical questions related to DILI ✓ Explore setup an EASL SIG Group. Possibility to meet at each EASL meeting
WG 2 DILI RISK STRATIFICATION	
Systematically review (and develop if needed) techniques and tools to evaluate the risk of DILI, quantify the degree of injury and impairment of function, and model clinical outcomes	<ul style="list-style-type: none"> ✓ EU Framework translational research plan for biomarker development
WG 3 PRECLINICAL EVALUATION OF DILI	
Review in vitro and in silico models of hepatotoxicity and critically appraise their strengths, limitations and applications in pre-clinical evaluation	<ul style="list-style-type: none"> ✓ Set up STSMs and research exchange programs for ECIs to enhance research skills & techniques
WG 4 CLINICAL TRIALS	
Define threshold criteria for patient inclusion in special patient populations monitoring plans, stopping rules, safety signals and outcome parameters to optimally plan future clinical trials; Review and evaluate therapeutic options for patients with DILI	<ul style="list-style-type: none"> ✓ Set up STSMs and exchange programs for ECIs with the Regulatory Agencies
WG 5 KNOWLEDGE DISSEMINATION	
Coordinate the set-up and maintenance of the Website and social networks promotion of the Action and maintain updated information on recent activities and downloadable resources;	<ul style="list-style-type: none"> ✓ Website setup, social media & updates ✓ Quality plan and good practice policies ✓ Meeting with IAIH Group or Societies oncology or those that use immune checkpoints inhibitors